Document Context

Nature of Disclosure: Regulatory filing pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, containing the transcript of an analyst and institutional investor meeting.

Management Participants

The meeting was led by key management personnel:

  • Mr. Herjit Bhalla – Chief Executive Officer – India Business – Dabur India Limited
  • Mr. Ankush Jain – Chief Financial Officer – Dabur India Limited
  • Mr. Rahul Sarawagi – Head, Investor Relations and M&A – Dabur India Limited

Executive Summary and Strategic Review

CEO Herjit Bhalla provided a comprehensive review of his first 6 months at the helm and an assessment of the company's 3-year strategic vision, which is 18 months into its cycle.

Company Overview and Heritage

  • Dabur is described as an organization with a 142-year rich heritage and deep consumer trust, present in 8 out of 10 Indian households.
  • The portfolio spans Home & Personal Care (HPC), Healthcare, Food & Beverages (F&B), and Ayurveda, with strong, category-defining brands.

Vision 2028 Pillars: 18-Month Assessment

Management provided a candid report card on the seven pillars of their strategic vision:

1. Accelerate Core Brands (Amber Rating): Core brands contribute ~60% of revenue. Growth was achieved but media spending fell short of commitments due to a hyperinflationary environment. Digital media spend now constitutes 43% of total A&P.

2. Premiumization (Amber/Green Rating): The premium portfolio contribution increased from 17% to 20% of revenue, growing at 4x the company's overall rate and is margin-accretive. Examples include organic honey, region-specific honey, and activated charcoal toothpaste.

3. Bold Bets in Health & Wellness (Amber Rating): The digestive portfolio (Hajmola, Pudin Hara, Isabgol) delivered strong double-digit growth. However, management sees more headroom for growth in functional beverages and strength/vitality products.

4. Portfolio Simplification (Green Rating): The company rationalized its portfolio, discontinuing 6 brands and 350 SKUs.

5. Go-to-Market Enhancement - Project Saksham (Green Rating): A massive distribution consolidation reduced the distributor count by 43%. This led to an 80% reduction in distributor attrition, 2x increase in their throughput, and a 30% improvement in their ROI. General Trade (GT) growth returned to mid-single digits for two consecutive quarters, with Q2 FY27 being the highest in 19 quarters.

6. Strategic M&A (Red Rating): A key gap area. The company acquired Badshah Masala and is integrating Sesa (effective retrospectively from April 1). Its venture arm, Dabur Ventures, made a minority investment in RAS. The board is seeking strategic fits that offer synergies and come at the right valuation, not just for the sake of M&A.

7. Operating Efficiencies - Project Samriddhi (Green Rating): Generated cost savings of INR 115 crore during the vision period, aligned with set goals.

New Growth Mantra: 'Ignite' Initiative

Management announced 'Ignite', a new mantra to reignite the organization, focused on four immediate priorities:

1. Accelerate Growth:

  • Energize the core and scale the 'star' brands by increasing consumer-facing A&P investments by 150-200 basis points.
  • Disproportionate investment in OTCs, digestives, skincare, home care, and foods.
  • Reiterated double-digit revenue growth guidance for the full year FY27.

2. Execution Excellence:

  • Shift focus from quantity to quality of coverage.
  • Launching 'Retail Next' program across 40,000 stores, aiming for growth 1.5x that of the rest of GT.
  • Enhancing direct rural reach to over 100,000 geotagged villages.
  • Alternate channels (e-commerce, quick commerce) are growing at a strong double-digit clip and are seen as complementary.

3. Future-Ready Portfolio:

  • Aim to increase the premium portfolio contribution to 23% within the next 18 months.
  • Strengthen the health and wellness play.
  • Continue pursuing strategic M&A in adjacent categories at the right valuation.

4. Operating Efficiencies:

  • Target to generate INR 170-200 crore in savings (1.5x previous savings) through initiatives like Saksham, Samriddhi, and a new IRIS/CRS program for forecasting accuracy.
  • Savings will be ploughed back into funding growth initiatives.

Q2 FY27 Financial and Operational Performance

  • Consolidated Revenue: Grew 11.6% year-on-year.
  • India Standalone Business: Grew 8.9% year-on-year. Margins diluted by only 10 basis points despite significant inflation, particularly in HPC.
  • India FMCG Business: Grew 10.7%, comprising 5.5% volume growth and 5.2% price growth.
  • International Business: Sustained strong momentum with 20% growth.
  • Segment-wise Performance:
  • HPC: Delivered double-digit growth.
  • Healthcare: Grew 6.9%, showing recovery from previous challenges.
  • F&B: Sustained accelerated, strong double-digit growth. Beverages bounced back on a good season and premium innovations like Real Activ.
  • This was the second consecutive quarter of double-digit revenue growth and the fourth consecutive quarter of double-digit Profit After Tax (PAT) growth.

Key Highlights from Q&A Session

  • M&A Strategy: Management expressed confidence in pursuing M&A but refused to be locked into an 18-month timeline, emphasizing strategic fit and valuation discipline.
  • D2C Initiatives: The company is nurturing D2C through 'Dabur Shop' and its own brand 'Siens by Dabur' in nutraceuticals. The Sesa integration will further bolster this.
  • Product Revival (Chyawanprash & Beverages): For Chyawanprash, strategies include new communication, new formats (gummies), and strong winter loading. For beverages, the focus is on premiumization (Real Activ, coconut water) to sustain momentum.
  • Management Structure: Confirmed there will be no new Global CEO. Herjit Bhalla, on the board, focuses on India and SAARC, while the international business runs independently under Mr. Narang's oversight.
  • Funding Growth: Incremental investments will be funded by operating efficiencies (targeting INR 170-200 cr savings) and a strong balance sheet (~INR 6,000 crore war chest in India for inorganic opportunities).
  • Portfolio Focus: Health & Wellness (OTC, digestives) and Premium F&B were highlighted as key growth vectors, while HPC remains the core profit generator.
  • Channel Strategy: The chemist channel is a critical part of Project Saksham and is a key focus area for driving healthcare growth.

Forward-Looking Statements

  • The company is initiating a new strategic exercise to develop a medium-term vision plan for 2031, with details to be shared in the next 6-8 months.
  • The management remains focused on controlling inflation, driving premiumization, and executing the 'Ignite' initiative to deliver on its guidance.